Trial Profile
A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Bicalutamide (Primary) ; Docetaxel (Primary) ; Antiandrogens
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PSA-ERECT
- 30 Jul 2011 New trial record